|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine affects the localization of TARDBP protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in decreased expression of SLC1A2 protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of APP protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of GSK3B protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of IL6 protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of MAP1LC3B protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased phosphorylation of MAPT protein] |
CTD |
PMID:30476904 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of APP protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of APP protein] |
CTD |
PMID:30476904 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Serine results in increased expression of ATF4 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
Serine results in increased expression of ATF6 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf6b |
activating transcription factor 6 beta |
increases expression |
ISO |
Serine results in increased expression of ATF6B mRNA |
CTD |
PMID:29098664 |
|
NCBI chr20:4,090,921...4,098,920
Ensembl chr20:4,090,921...4,098,894
|
|
G |
Atxn3 |
ataxin 3 |
increases expression |
ISO |
Serine results in increased expression of ATXN3 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Serine results in increased expression of BAX mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Serine results in increased expression of CALR mRNA |
CTD |
PMID:29098664 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Canx |
calnexin |
increases expression |
ISO |
Serine results in increased expression of CANX mRNA |
CTD |
PMID:29098664 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Cct4 |
chaperonin containing TCP1 subunit 4 |
increases expression |
ISO |
Serine results in increased expression of CCT4 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr14:96,991,853...97,004,732
Ensembl chr14:96,991,859...97,005,267
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
increases expression |
ISO |
Serine results in increased expression of CCT7 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
Serine results in decreased expression of CEBPB mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cs |
citrate synthase |
decreases activity |
EXP |
Serine analog results in decreased activity of CS protein |
CTD |
PMID:19733154 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Derl2 |
derlin 2 |
increases expression |
ISO |
Serine results in increased expression of DERL2 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr10:55,727,764...55,739,442
Ensembl chr10:55,727,643...55,739,518
|
|
G |
Dnajb2 |
DnaJ heat shock protein family (Hsp40) member B2 |
increases expression |
ISO |
Serine results in increased expression of DNAJB2 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 9:76,731,060...76,739,278
Ensembl chr 9:76,731,065...76,739,277
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
Serine results in increased expression of DNAJB9 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
increases expression |
ISO |
Serine results in increased expression of DNAJC3 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnajc4 |
DnaJ heat shock protein family (Hsp40) member C4 |
increases expression |
ISO |
Serine results in increased expression of DNAJC4 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
increases expression |
ISO |
Serine results in increased expression of EDEM1 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases expression |
ISO |
Serine results in increased expression of EIF2A mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Erp44 |
endoplasmic reticulum protein 44 |
increases expression |
ISO |
Serine results in increased expression of ERP44 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 5:62,516,550...62,610,762
Ensembl chr 5:62,516,551...62,610,761
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of GSK3B protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of GSK3B protein] |
CTD |
PMID:30476904 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
Serine results in increased expression of HERPUD1 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Serine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
ISO |
Serine results in decreased expression of HSPA1B mRNA |
CTD |
PMID:29098664 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
increases expression |
ISO |
Serine results in increased expression of HSPA1L mRNA |
CTD |
PMID:29098664 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Htra4 |
HtrA serine peptidase 4 |
decreases expression |
ISO |
Serine results in decreased expression of HTRA4 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr16:67,001,605...67,015,074
Ensembl chr16:67,001,605...67,015,074
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of IL6 protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of IL6 protein] |
CTD |
PMID:30476904 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine affects the localization of TARDBP protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in decreased expression of SLC1A2 protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of APP protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of GSK3B protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of IL6 protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of MAP1LC3B protein]; [LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased phosphorylation of MAPT protein] |
CTD |
PMID:30476904 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of MAP1LC3B protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine results in increased expression of MAP1LC3B protein] |
CTD |
PMID:30476904 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
decreases expression |
ISO |
Serine results in decreased expression of MAPK10 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in increased phosphorylation of MAPT protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine results in increased phosphorylation of MAPT protein] |
CTD |
PMID:30476904 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression |
ISO |
Serine results in increased expression of P4HB protein |
CTD |
PMID:28975502 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
ISO |
Serine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine results in decreased expression of SLC1A2 protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine results in decreased expression of SLC1A2 protein] |
CTD |
PMID:30476904 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
Serine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srr |
serine racemase |
multiple interactions |
EXP |
SRR protein results in increased abundance of and results in increased secretion of Serine analog |
CTD |
PMID:27387750 |
|
NCBI chr10:59,769,563...59,786,688
Ensembl chr10:59,769,571...59,787,011
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
EXP |
[LAMC1 protein modified form co-treated with ANGPT1 protein co-treated with Serine] inhibits the reaction [beta-N-methylamino-L-alanine affects the localization of TARDBP protein]; Serine inhibits the reaction [beta-N-methylamino-L-alanine affects the localization of TARDBP protein] |
CTD |
PMID:30476904 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Ube2g2 |
ubiquitin-conjugating enzyme E2G 2 |
decreases expression |
ISO |
Serine results in decreased expression of UBE2G2 mRNA |
CTD |
PMID:29098664 |
|
NCBI chr20:10,983,734...11,005,468
Ensembl chr20:10,983,742...11,005,447
|
|
G |
Vcp |
valosin-containing protein |
decreases expression |
ISO |
Serine results in decreased expression of VCP mRNA |
CTD |
PMID:29098664 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression multiple interactions decreases expression |
ISO |
goralatide results in increased expression of ACE mRNA [BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA] goralatide results in decreased expression of ACE mRNA |
CTD |
PMID:20096676 PMID:33007385 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] |
CTD |
PMID:33007385 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein] goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
affects abundance multiple interactions |
ISO |
BDKRB1 protein affects the abundance of goralatide [BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide |
CTD |
PMID:20096676 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gli2 |
GLI family zinc finger 2 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein] |
CTD |
PMID:31181250 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Gli3 |
GLI family zinc finger 3 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] |
CTD |
PMID:33007385 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
affects binding |
ISO |
phenylalanylserine analog binds to SLC15A1 protein |
CTD |
PMID:21147219 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|